# EU-1-16-1165_public-assessment-report_20170313_20200220_lifmior-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES
HEALTH
17 July 2017
EMA/114647/2016 Corr. 1
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
LIFMIOR
International non-proprietary name: etanercept
Medicinal product no longer authorised
Procedure No. EMEA/H/C/004167/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
4
1.1. Submission of the dossier
4
C
Medicinal Product no longer authorised
Rheumatoid arthritis
Juvenile idiopathic arthritis
Psoriatic arthritis
Ankylosing spondylitis (AS)
5
Plaque psoriasis.
5
Paediatric plaque psoriasis
5
1.2. Steps taken for the assessment of the product
6
2. Scientific discussion
7
2.1. Introduction
7
2.2. Quality aspects
8
2.2.1. Introduction
8
2.2.2. Conclusions on the chemical, pharmaceutical and biological aspects
8
2.3. Non-clinical aspects
8
2.3.1. Introduction
8
2.3.2. Ecotoxicity/environmental risk assessment
8
2.3.3. Discussion on non-clinical aspects
9
2.3.4. Conclusion on the non-clinical aspeo's
9
2.4. Clinical aspects
9
2.4.1. Introduction
9
2.4.2. Pharmacokinetics
9
2.4.3. Pharmacodynamics
9
2.4.4. Post marketing experience
9
2.4.5. Discussion on clinical aspects
9
2.4.6. Conclusions of clinical aspects
10
2.5. Risk management Nan
10
2.6. PSUR subme
16
avance
16
2.8. Product information
16
2.8.1.
er consultation
16
2.8
16
Ational monitoring
Benefit-risk balance
16
Recommendation
17
Assessment report
EMA/114647/2017
Page 2/19
